[ET Net News Agency, 11 November 2021] Luye Pharma Group Ltd. (02186) said Luye Pharma
Switzerland AG (Luye Switzerland), a wholly owned subsidiary of the company, and Zambon
Switzerland (Zambon) have entered into an agreement under which Zambon was granted the
exclusive rights to commercialize the new drug, Rivastigmine Multi-Day Transdermal Patch
(Rivastigmine MD or LY30410), in Switzerland.
Rivastigmine MD is a twice-weekly innovative patch formulation for the treatment of mild
to moderate dementia associated with Alzheimer's disease. It was developed by the group on
its proprietary transdermal patch platform and is one of the group's core products in the
CNS therapeutic field. (RC)